You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Novo Nordisk’s obesity drug Wegovy was approved in China on Tuesday, though the company has not announced launch plans and starter doses in the U.S. have been in short supply for months.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race ...

Wegovy was just approved in China. Novo Nordisk (NVO-1.39%) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1 ...

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit ...

China's market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030 As Novo Nordisk's patent on semaglutide expires in 2026, some companies are already seeking to produce ...

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk NOVO.B 3.06 % increase; green up pointing triangle to begin selling it in the world’s second ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S. prices. Wegovy's approval by China's NMPA targets individuals with a BMI ...

Novo Nordisk A/S will restrict initial sales of its blockbuster obesity treatment Wegovy in China, as the drugmaker grapples with how to control access to the medicine for the world’s biggest ...